Oxaliplatin plus fluoropyrimidines as adjuvant therapy for colon cancer in older patients: A subgroup analysis from the TOSCA trial

G. Rosati; S. Lonardi; F. Galli; M. Di Bartolomeo; M. Ronzoni; M.G. Zampino; M. Banzi; A. Zaniboni; F. Pasini; S. Bozzarelli; S.K. Garattini; D. Ferrari; V. Montesarchio; A. Mambrini; L. Ciuffreda; F. Galli; V. Pusceddu; C. Carlomagno; P. Bidoli; D. Amoroso; A.M. Bochicchio; L. Frassineti; D. Corsi; D. Bilancia; A. Pastorino; A. De Stefano; R. Labianca; D. Bilancia; G. Rosati; V. Montesarchio; R.V. Iaffaioli; G. Nasti; B. Daniele; V. Zagonel; N. Pella; G. Aprile; F. Pasini; R.P. Marchetti; A. Romiti; D. Ferrari; P. Foa; A. Zaniboni; S. Mosconi; A. Sobrero; P. Bidoli; M. Cazzaniga; G.D. Beretta; D.C. Corsi; E. Cortesi; S. Barni; F. Petrelli; P. Allione; A.M. D'Arco; G. Valmadre; E. Piazza; E. Veltri; G.V. Ramus; L. Giustini; S. Tumulo; S. Cascinu; C. Granetto; F. Testore; M. Giordano; M. Moroni; M. Di Seri; A. Nuzzo; L. Angelelli; S. Gori; G. Farina; M. Aglietta; R. Franchi; M. Comandé; P. Giordani; G. Tonini; E. Bucci; A. Ballestrero; M. Benasso; C. Graiff; S. Bravi; O. Caffo; R.R. Silva; L. Frontini; S. Rota; L. Cozzi; M. Cantore; E. Maiello; S. Cinieri; N. Silvestris; S. Romito; V. Gebbia; M. Banzi; A. Santoro; F. Artioli; R. Mattioli; A. Contu; F. Di Costanzo; F. Leonardi; L. Cavanna; R. Passalacqua; D. Amoroso; P. Sozzi; M. D'Amico; D. Amadori; L. Frassineti; D. Turci; A. Ravaioli; E. Pasquini; A. Gambi; M. Faedi; G. Cruciani; E. Bajetta; M. Di Bartolomeo; L. Gianni; M.T. Ionta; B. Massidda; M. Scartozzi; M.G. Zampino; A.M. Bochicchio; A. Ciarlo; A. Di Leo; S. Frustaci; G. Rangoni; A. Arizzoia; L. Pavesi; C. Verusio; G. Pinotti; A. Iop; S. De Placido; C. Carlomagno; V. Adamo; C. Ficorella; D. Natale; E. Greco; E. Rulli; F. Galli; D. Poli; L. Porcu; V. Torri

doi:10.1016/j.ejca.2021.01.051

Oxaliplatin plus fluoropyrimidines as adjuvant therapy for colon cancer in older patients: A subgroup analysis from the TOSCA trial

G. Rosati, S. Lonardi, F. Galli, M. Di Bartolomeo, M. Ronzoni, M.G. Zampino, M. Banzi, A. Zaniboni, F. Pasini, S. Bozzarelli, S.K. Garattini, D. Ferrari, V. Montesarchio, A. Mambrini, L. Ciuffreda, F. Galli, V. Pusceddu, C. Carlomagno, P. Bidoli, D. AmorosoA.M. Bochicchio, L. Frassineti, D. Corsi, D. Bilancia, A. Pastorino, A. De Stefano, R. Labianca, D. Bilancia, G. Rosati, V. Montesarchio, R.V. Iaffaioli, G. Nasti, B. Daniele, V. Zagonel, N. Pella, G. Aprile, F. Pasini, R.P. Marchetti, A. Romiti, D. Ferrari, P. Foa, A. Zaniboni, S. Mosconi, A. Sobrero, P. Bidoli, M. Cazzaniga, G.D. Beretta, D.C. Corsi, E. Cortesi, S. Barni, F. Petrelli, P. Allione, A.M. D'Arco, G. Valmadre, E. Piazza, E. Veltri, G.V. Ramus, L. Giustini, S. Tumulo, S. Cascinu, C. Granetto, F. Testore, M. Giordano, M. Moroni, M. Di Seri, A. Nuzzo, L. Angelelli, S. Gori, G. Farina, M. Aglietta, R. Franchi, M. Comandé, P. Giordani, G. Tonini, E. Bucci, A. Ballestrero, M. Benasso, C. Graiff, S. Bravi, O. Caffo, R.R. Silva, L. Frontini, S. Rota, L. Cozzi, M. Cantore, E. Maiello, S. Cinieri, N. Silvestris, S. Romito, V. Gebbia, M. Banzi, A. Santoro, F. Artioli, R. Mattioli, A. Contu, F. Di Costanzo, F. Leonardi, L. Cavanna, R. Passalacqua, D. Amoroso, P. Sozzi, M. D'Amico, D. Amadori, L. Frassineti, D. Turci, A. Ravaioli, E. Pasquini, A. Gambi, M. Faedi, G. Cruciani, E. Bajetta, M. Di Bartolomeo, L. Gianni, M.T. Ionta, B. Massidda, M. Scartozzi, M.G. Zampino, A.M. Bochicchio, A. Ciarlo, A. Di Leo, S. Frustaci, G. Rangoni, A. Arizzoia, L. Pavesi, C. Verusio, G. Pinotti, A. Iop, S. De Placido, C. Carlomagno, V. Adamo, C. Ficorella, D. Natale, E. Greco, E. Rulli, F. Galli, D. Poli, L. Porcu, V. Torri

Research output: Contribution to journal › Article › peer-review

Abstract

Background: Previous studies on oxaliplatin and fluoropyrimidines as adjuvant therapy in older patients with stage III colon cancer (CC) produced conflicting results. Patients and methods: We assessed the impact of age on time to tumour recurrence (TTR), disease-free survival (DFS), cancer-specific survival (CSS), and overall survival (OS) in 2360 patients with stage III CC (1667 aged

Original language	English
Pages (from-to)	190-201
Number of pages	12
Journal	European Journal of Cancer
Volume	148
DOIs	https://doi.org/10.1016/j.ejca.2021.01.051
Publication status	Published - 2021

Keywords

capecitabine plus oxaliplatin
fluoropyrimidine
oxaliplatin
antineoplastic agent
capecitabine
fluorouracil
folinic acid
adjuvant therapy
adult
aged
Article
cancer specific survival
cancer staging
colon cancer
controlled study
disease free survival
drug efficacy
female
follow up
human
major clinical study
male
overall survival
patient compliance
post hoc analysis
priority journal
treatment interruption
tumor recurrence
adjuvant chemotherapy
colon tumor
middle aged
mortality
pathology
prognosis
survival rate
very elderly
Adult
Aged
80 and over
Antineoplastic Combined Chemotherapy Protocols
Capecitabine
Chemotherapy
Adjuvant
Colonic Neoplasms
Female
Fluorouracil
Follow-Up Studies
Humans
Leucovorin
Male
Middle Aged
Neoplasm Recurrence
Local
Oxaliplatin
Prognosis
Survival Rate

Access to Document

10.1016/j.ejca.2021.01.051

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85102832289&doi=10.1016%2fj.ejca.2021.01.051&partnerID=40&md5=5f67cfb331d2b7919e38cdc34923bc17

Cite this

Rosati, G., Lonardi, S., Galli, F., Di Bartolomeo, M., Ronzoni, M., Zampino, M. G., Banzi, M., Zaniboni, A., Pasini, F., Bozzarelli, S., Garattini, S. K., Ferrari, D., Montesarchio, V., Mambrini, A., Ciuffreda, L., Galli, F., Pusceddu, V., Carlomagno, C., Bidoli, P., ... Torri, V. (2021). Oxaliplatin plus fluoropyrimidines as adjuvant therapy for colon cancer in older patients: A subgroup analysis from the TOSCA trial. European Journal of Cancer, 148, 190-201. https://doi.org/10.1016/j.ejca.2021.01.051

Rosati, G , Lonardi, S, Galli, F, Di Bartolomeo, M , Ronzoni, M , Zampino, MG , Banzi, M , Zaniboni, A, Pasini, F, Bozzarelli, S , Garattini, SK , Ferrari, D, Montesarchio, V, Mambrini, A, Ciuffreda, L, Galli, F, Pusceddu, V, Carlomagno, C, Bidoli, P, Amoroso, D, Bochicchio, AM, Frassineti, L, Corsi, D, Bilancia, D, Pastorino, A, De Stefano, A, Labianca, R, Bilancia, D, Rosati, G, Montesarchio, V, Iaffaioli, RV, Nasti, G, Daniele, B, Zagonel, V, Pella, N, Aprile, G, Pasini, F, Marchetti, RP, Romiti, A , Ferrari, D, Foa, P, Zaniboni, A, Mosconi, S, Sobrero, A, Bidoli, P, Cazzaniga, M, Beretta, GD, Corsi, DC, Cortesi, E, Barni, S, Petrelli, F, Allione, P, D'Arco, AM, Valmadre, G, Piazza, E, Veltri, E, Ramus, GV, Giustini, L, Tumulo, S, Cascinu, S, Granetto, C, Testore, F, Giordano, M , Moroni, M, Di Seri, M, Nuzzo, A, Angelelli, L, Gori, S, Farina, G , Aglietta, M, Franchi, R, Comandé, M, Giordani, P, Tonini, G, Bucci, E, Ballestrero, A, Benasso, M, Graiff, C, Bravi, S, Caffo, O, Silva, RR, Frontini, L, Rota, S, Cozzi, L, Cantore, M, Maiello, E, Cinieri, S, Silvestris, N, Romito, S, Gebbia, V, Banzi, M , Santoro, A, Artioli, F, Mattioli, R, Contu, A, Di Costanzo, F, Leonardi, F, Cavanna, L, Passalacqua, R, Amoroso, D, Sozzi, P, D'Amico, M, Amadori, D, Frassineti, L, Turci, D, Ravaioli, A, Pasquini, E, Gambi, A, Faedi, M, Cruciani, G, Bajetta, E, Di Bartolomeo, M, Gianni, L, Ionta, MT, Massidda, B, Scartozzi, M, Zampino, MG, Bochicchio, AM, Ciarlo, A, Di Leo, A, Frustaci, S, Rangoni, G, Arizzoia, A, Pavesi, L, Verusio, C, Pinotti, G, Iop, A, De Placido, S, Carlomagno, C, Adamo, V, Ficorella, C, Natale, D, Greco, E , Rulli, E, Galli, F, Poli, D , Porcu, L & Torri, V 2021, 'Oxaliplatin plus fluoropyrimidines as adjuvant therapy for colon cancer in older patients: A subgroup analysis from the TOSCA trial', European Journal of Cancer, vol. 148, pp. 190-201. https://doi.org/10.1016/j.ejca.2021.01.051

@article{c97c35e8bb3a40f09d617fa23528aab7,

title = "Oxaliplatin plus fluoropyrimidines as adjuvant therapy for colon cancer in older patients: A subgroup analysis from the TOSCA trial",

abstract = "Background: Previous studies on oxaliplatin and fluoropyrimidines as adjuvant therapy in older patients with stage III colon cancer (CC) produced conflicting results. Patients and methods: We assessed the impact of age on time to tumour recurrence (TTR), disease-free survival (DFS), cancer-specific survival (CSS), and overall survival (OS) in 2360 patients with stage III CC (1667 aged ",

keywords = "capecitabine plus oxaliplatin, fluoropyrimidine, oxaliplatin, antineoplastic agent, capecitabine, fluorouracil, folinic acid, adjuvant therapy, adult, aged, Article, cancer specific survival, cancer staging, colon cancer, controlled study, disease free survival, drug efficacy, female, follow up, human, major clinical study, male, overall survival, patient compliance, post hoc analysis, priority journal, treatment interruption, tumor recurrence, adjuvant chemotherapy, colon tumor, middle aged, mortality, pathology, prognosis, survival rate, very elderly, Adult, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Capecitabine, Chemotherapy, Adjuvant, Colonic Neoplasms, Female, Fluorouracil, Follow-Up Studies, Humans, Leucovorin, Male, Middle Aged, Neoplasm Recurrence, Local, Oxaliplatin, Prognosis, Survival Rate",

author = "G. Rosati and S. Lonardi and F. Galli and {Di Bartolomeo}, M. and M. Ronzoni and M.G. Zampino and M. Banzi and A. Zaniboni and F. Pasini and S. Bozzarelli and S.K. Garattini and D. Ferrari and V. Montesarchio and A. Mambrini and L. Ciuffreda and F. Galli and V. Pusceddu and C. Carlomagno and P. Bidoli and D. Amoroso and A.M. Bochicchio and L. Frassineti and D. Corsi and D. Bilancia and A. Pastorino and {De Stefano}, A. and R. Labianca and D. Bilancia and G. Rosati and V. Montesarchio and R.V. Iaffaioli and G. Nasti and B. Daniele and V. Zagonel and N. Pella and G. Aprile and F. Pasini and R.P. Marchetti and A. Romiti and D. Ferrari and P. Foa and A. Zaniboni and S. Mosconi and A. Sobrero and P. Bidoli and M. Cazzaniga and G.D. Beretta and D.C. Corsi and E. Cortesi and S. Barni and F. Petrelli and P. Allione and A.M. D'Arco and G. Valmadre and E. Piazza and E. Veltri and G.V. Ramus and L. Giustini and S. Tumulo and S. Cascinu and C. Granetto and F. Testore and M. Giordano and M. Moroni and {Di Seri}, M. and A. Nuzzo and L. Angelelli and S. Gori and G. Farina and M. Aglietta and R. Franchi and M. Comand{\'e} and P. Giordani and G. Tonini and E. Bucci and A. Ballestrero and M. Benasso and C. Graiff and S. Bravi and O. Caffo and R.R. Silva and L. Frontini and S. Rota and L. Cozzi and M. Cantore and E. Maiello and S. Cinieri and N. Silvestris and S. Romito and V. Gebbia and M. Banzi and A. Santoro and F. Artioli and R. Mattioli and A. Contu and {Di Costanzo}, F. and F. Leonardi and L. Cavanna and R. Passalacqua and D. Amoroso and P. Sozzi and M. D'Amico and D. Amadori and L. Frassineti and D. Turci and A. Ravaioli and E. Pasquini and A. Gambi and M. Faedi and G. Cruciani and E. Bajetta and {Di Bartolomeo}, M. and L. Gianni and M.T. Ionta and B. Massidda and M. Scartozzi and M.G. Zampino and A.M. Bochicchio and A. Ciarlo and {Di Leo}, A. and S. Frustaci and G. Rangoni and A. Arizzoia and L. Pavesi and C. Verusio and G. Pinotti and A. Iop and {De Placido}, S. and C. Carlomagno and V. Adamo and C. Ficorella and D. Natale and E. Greco and E. Rulli and F. Galli and D. Poli and L. Porcu and V. Torri",

note = "cited By 1",

year = "2021",

doi = "10.1016/j.ejca.2021.01.051",

language = "English",

volume = "148",

pages = "190--201",

journal = "European Journal of Cancer",

issn = "0959-8049",

publisher = "Elsevier Ltd",

}

TY - JOUR

T1 - Oxaliplatin plus fluoropyrimidines as adjuvant therapy for colon cancer in older patients: A subgroup analysis from the TOSCA trial

AU - Rosati, G.

AU - Lonardi, S.

AU - Galli, F.

AU - Di Bartolomeo, M.

AU - Ronzoni, M.

AU - Zampino, M.G.

AU - Banzi, M.

AU - Zaniboni, A.

AU - Pasini, F.

AU - Bozzarelli, S.

AU - Garattini, S.K.

AU - Ferrari, D.

AU - Montesarchio, V.

AU - Mambrini, A.

AU - Ciuffreda, L.

AU - Galli, F.

AU - Pusceddu, V.

AU - Carlomagno, C.

AU - Bidoli, P.

AU - Amoroso, D.

AU - Bochicchio, A.M.

AU - Frassineti, L.

AU - Corsi, D.

AU - Bilancia, D.

AU - Pastorino, A.

AU - De Stefano, A.

AU - Labianca, R.

AU - Bilancia, D.

AU - Rosati, G.

AU - Montesarchio, V.

AU - Iaffaioli, R.V.

AU - Nasti, G.

AU - Daniele, B.

AU - Zagonel, V.

AU - Pella, N.

AU - Aprile, G.

AU - Pasini, F.

AU - Marchetti, R.P.

AU - Romiti, A.

AU - Ferrari, D.

AU - Foa, P.

AU - Zaniboni, A.

AU - Mosconi, S.

AU - Sobrero, A.

AU - Bidoli, P.

AU - Cazzaniga, M.

AU - Beretta, G.D.

AU - Corsi, D.C.

AU - Cortesi, E.

AU - Barni, S.

AU - Petrelli, F.

AU - Allione, P.

AU - D'Arco, A.M.

AU - Valmadre, G.

AU - Piazza, E.

AU - Veltri, E.

AU - Ramus, G.V.

AU - Giustini, L.

AU - Tumulo, S.

AU - Cascinu, S.

AU - Granetto, C.

AU - Testore, F.

AU - Giordano, M.

AU - Moroni, M.

AU - Di Seri, M.

AU - Nuzzo, A.

AU - Angelelli, L.

AU - Gori, S.

AU - Farina, G.

AU - Aglietta, M.

AU - Franchi, R.

AU - Comandé, M.

AU - Giordani, P.

AU - Tonini, G.

AU - Bucci, E.

AU - Ballestrero, A.

AU - Benasso, M.

AU - Graiff, C.

AU - Bravi, S.

AU - Caffo, O.

AU - Silva, R.R.

AU - Frontini, L.

AU - Rota, S.

AU - Cozzi, L.

AU - Cantore, M.

AU - Maiello, E.

AU - Cinieri, S.

AU - Silvestris, N.

AU - Romito, S.

AU - Gebbia, V.

AU - Banzi, M.

AU - Santoro, A.

AU - Artioli, F.

AU - Mattioli, R.

AU - Contu, A.

AU - Di Costanzo, F.

AU - Leonardi, F.

AU - Cavanna, L.

AU - Passalacqua, R.

AU - Amoroso, D.

AU - Sozzi, P.

AU - D'Amico, M.

AU - Amadori, D.

AU - Frassineti, L.

AU - Turci, D.

AU - Ravaioli, A.

AU - Pasquini, E.

AU - Gambi, A.

AU - Faedi, M.

AU - Cruciani, G.

AU - Bajetta, E.

AU - Di Bartolomeo, M.

AU - Gianni, L.

AU - Ionta, M.T.

AU - Massidda, B.

AU - Scartozzi, M.

AU - Zampino, M.G.

AU - Bochicchio, A.M.

AU - Ciarlo, A.

AU - Di Leo, A.

AU - Frustaci, S.

AU - Rangoni, G.

AU - Arizzoia, A.

AU - Pavesi, L.

AU - Verusio, C.

AU - Pinotti, G.

AU - Iop, A.

AU - De Placido, S.

AU - Carlomagno, C.

AU - Adamo, V.

AU - Ficorella, C.

AU - Natale, D.

AU - Greco, E.

AU - Rulli, E.

AU - Galli, F.

AU - Poli, D.

AU - Porcu, L.

AU - Torri, V.

N1 - cited By 1

PY - 2021

Y1 - 2021

N2 - Background: Previous studies on oxaliplatin and fluoropyrimidines as adjuvant therapy in older patients with stage III colon cancer (CC) produced conflicting results. Patients and methods: We assessed the impact of age on time to tumour recurrence (TTR), disease-free survival (DFS), cancer-specific survival (CSS), and overall survival (OS) in 2360 patients with stage III CC (1667 aged

AB - Background: Previous studies on oxaliplatin and fluoropyrimidines as adjuvant therapy in older patients with stage III colon cancer (CC) produced conflicting results. Patients and methods: We assessed the impact of age on time to tumour recurrence (TTR), disease-free survival (DFS), cancer-specific survival (CSS), and overall survival (OS) in 2360 patients with stage III CC (1667 aged

KW - capecitabine plus oxaliplatin

KW - fluoropyrimidine

KW - oxaliplatin

KW - antineoplastic agent

KW - capecitabine

KW - fluorouracil

KW - folinic acid

KW - adjuvant therapy

KW - adult

KW - aged

KW - Article

KW - cancer specific survival

KW - cancer staging

KW - colon cancer

KW - controlled study

KW - disease free survival

KW - drug efficacy

KW - female

KW - follow up

KW - human

KW - major clinical study

KW - male

KW - overall survival

KW - patient compliance

KW - post hoc analysis

KW - priority journal

KW - treatment interruption

KW - tumor recurrence

KW - adjuvant chemotherapy

KW - colon tumor

KW - middle aged

KW - mortality

KW - pathology

KW - prognosis

KW - survival rate

KW - very elderly

KW - Adult

KW - Aged

KW - 80 and over

KW - Antineoplastic Combined Chemotherapy Protocols

KW - Capecitabine

KW - Chemotherapy

KW - Adjuvant

KW - Colonic Neoplasms

KW - Female

KW - Fluorouracil

KW - Follow-Up Studies

KW - Humans

KW - Leucovorin

KW - Male

KW - Middle Aged

KW - Neoplasm Recurrence

KW - Local

KW - Oxaliplatin

KW - Prognosis

KW - Survival Rate

U2 - 10.1016/j.ejca.2021.01.051

DO - 10.1016/j.ejca.2021.01.051

M3 - Article

SN - 0959-8049

VL - 148

SP - 190

EP - 201

JO - European Journal of Cancer

JF - European Journal of Cancer

ER -

Oxaliplatin plus fluoropyrimidines as adjuvant therapy for colon cancer in older patients: A subgroup analysis from the TOSCA trial

Abstract

Keywords

Access to Document

Fingerprint

Cite this